688658 悦康药业
已收盘 05-12 15:00:00
资讯
新帖
简况
公告精选︱悦康药业:拟投资10亿元建设核酸药物基地项目;金螳螂:目前未从事商业航天核心产业,亦未开展数据中心算力运营业务
格隆汇 · 05-07
公告精选︱悦康药业:拟投资10亿元建设核酸药物基地项目;金螳螂:目前未从事商业航天核心产业,亦未开展数据中心算力运营业务
悦康药业(688658.SH)拟在杭州投资10亿元建设核酸药物基地项目
智通财经 · 05-07
悦康药业(688658.SH)拟在杭州投资10亿元建设核酸药物基地项目
悦康药业拟斥资约10亿元在杭州建设核酸药物生产基地
美股速递 · 05-07
悦康药业拟斥资约10亿元在杭州建设核酸药物生产基地
5月7日悦康药业涨5.21%,富国医药创新股票A基金重仓该股
证券之星 · 05-07
5月7日悦康药业涨5.21%,富国医药创新股票A基金重仓该股
股市必读:悦康药业(688658)股东户数1.48万户,较上期增加13.4%
证券之星 · 05-06
股市必读:悦康药业(688658)股东户数1.48万户,较上期增加13.4%
每周股票复盘:悦康药业(688658)Q1净亏收窄至-3310.6万元
证券之星 · 05-02
每周股票复盘:悦康药业(688658)Q1净亏收窄至-3310.6万元
悦康药业(688658)披露2026年第一季度报告,4月30日股价上涨1.71%
中金财经 · 04-30
悦康药业(688658)披露2026年第一季度报告,4月30日股价上涨1.71%
图解悦康药业一季报:第一季度单季净利润同比增长32.81%
证券之星 · 04-29
图解悦康药业一季报:第一季度单季净利润同比增长32.81%
每周股票复盘:悦康药业(688658)募投项目变更用于新药研发
证券之星 · 04-26
每周股票复盘:悦康药业(688658)募投项目变更用于新药研发
4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股
证券之星 · 04-22
4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股
4月15日悦康药业涨8.59%,富国精准医疗混合A基金重仓该股
证券之星 · 04-15
4月15日悦康药业涨8.59%,富国精准医疗混合A基金重仓该股
悦康药业最新公告:子公司YKYY026注射液获临床试验批准
证券之星 · 04-13
悦康药业最新公告:子公司YKYY026注射液获临床试验批准
悦康药业(688658)披露子公司YKYY018雾化吸入剂获人偏肺病毒感染临床试验批准,4月3日股价下跌3.07%
证券之星 · 04-03
悦康药业(688658)披露子公司YKYY018雾化吸入剂获人偏肺病毒感染临床试验批准,4月3日股价下跌3.07%
悦康药业最新公告:创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗
证券之星 · 04-02
悦康药业最新公告:创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗
股市必读:悦康药业(688658)今年截至3月26日累计跌幅已超20%
证券之星 · 03-27
股市必读:悦康药业(688658)今年截至3月26日累计跌幅已超20%
三部门发文规范中医药服务管理;药监局助力器械临床创新成果转化
21世纪经济报道 · 03-25
三部门发文规范中医药服务管理;药监局助力器械临床创新成果转化
悦康药业(688658.SH):YKYY018雾化吸入剂治疗与预防人偏肺病毒感染的适应症获FDA临床试验批准
智通财经 · 03-24
悦康药业(688658.SH):YKYY018雾化吸入剂治疗与预防人偏肺病毒感染的适应症获FDA临床试验批准
股市必读:悦康药业年报 - 第四季度单季净利润同比下降33.02%
证券之星 · 03-23
股市必读:悦康药业年报 - 第四季度单季净利润同比下降33.02%
每周股票复盘:悦康药业(688658)2025年净亏损2.62亿元
证券之星 · 03-22
每周股票复盘:悦康药业(688658)2025年净亏损2.62亿元
悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元
智通财经 · 03-20
悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元
加载更多
公司概况
公司名称:
悦康药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-24
主营业务:
悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是银杏叶提取物注射液、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠(自产)、注射用头孢呋辛钠(明可欣)、活心丸(浓缩丸)。公司连续多年入选工信部医药工业百强,连续多年入选工信部中国医药研发产品线最佳工业企业。在2025年第42届全国医药工业信息年会上公司又一次强势入围,并荣获“2025年中国医药研发产品线工业企业优秀案例”荣誉;此外,公司荣获“2025中国药品研发综合实力百强”、“2025中国中药研发实力”第6位等荣誉。公司已获国家科技进步二等奖2项,承担省部级以上科技项目50余项,国家级重大专项23项,已获授权专利400余项,公司创新能力持续增强。
发行价格:
24.36
{"stockData":{"symbol":"688658","market":"SH","secType":"STK","nameCN":"悦康药业","latestPrice":22.16,"timestamp":1778569200000,"preClose":21.88,"halted":0,"volume":11517426,"delay":0,"changeRate":0.0128,"floatShares":450000000,"shares":450000000,"eps":-0.5472,"marketStatus":"已收盘","change":0.28,"latestTime":"05-12 15:00:00","open":21.8,"high":22.56,"low":21.65,"amount":255000000,"amplitude":0.0416,"askPrice":22.18,"askSize":2,"bidPrice":22.16,"bidSize":37,"shortable":0,"etf":0,"ttmEps":-0.5472,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":5,"adr":0,"adjPreClose":21.88,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778549400000,1778556600000],[1778562000000,1778569200000]],"highLimit":24.07,"lowLimit":19.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":3.04,"roa":"--","roe":"--","epsLYR":-0.59,"committee":-0.167598,"marketValue":9972000000,"turnoverRate":0.0256,"status":0,"afterMarket":{"amount":0,"volume":0,"close":22.16,"buyVolume":0,"sellVolume":0,"time":1778571237558,"indexStatus":"已收盘 05-12 15:30:00","preClose":21.88},"floatMarketCap":9972000000},"requestUrl":"/m/hq/s/688658","defaultTab":"news","newsList":[{"id":"2633572125","title":"公告精选︱悦康药业:拟投资10亿元建设核酸药物基地项目;金螳螂:目前未从事商业航天核心产业,亦未开展数据中心算力运营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2633572125","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633572125?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:17","pubTimestamp":1778163460,"startTime":"0","endTime":"0","summary":"卡倍亿:拟发行可转债募资不超过5.1亿元","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4659337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0239","BK0183","DTCR","BK0178","UFO","BK0070","BK0028","688658","BK0145","BK0180","BK0187","BK0257","002081","BK4564","BLOK","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633148828","title":"悦康药业(688658.SH)拟在杭州投资10亿元建设核酸药物基地项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2633148828","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633148828?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:33","pubTimestamp":1778150031,"startTime":"0","endTime":"0","summary":"公司全资子公司杭州天龙药业有限公司为唯一投资方及项目实施主体。本次投资旨在依托杭州生物医药产业集聚、高端人才汇聚及产业配套完善的区位优势,承接公司现有核酸药物在研管线的研发及产业化,满足产品上市后的量产保障需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121270385","title":"悦康药业拟斥资约10亿元在杭州建设核酸药物生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=1121270385","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121270385?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:24","pubTimestamp":1778149454,"startTime":"0","endTime":"0","summary":"悦康药业集团宣布,公司计划投资约10亿元人民币,在杭州市打造核酸药物生产基地。这一重大投资举措标志着公司正式布局核酸药物这一前沿生物医药领域。\n核酸药物作为新一代生物技术药物,在遗传性疾病、肿瘤治疗等领域展现出巨大潜力。该生产基地的建设将进一步完善悦康药业在创新药物领域的产业布局,提升公司在生物医药领域的核心竞争力。\n此次投资预计将带动当地生物医药产业发展,创造更多就业机会,同时也将助力杭州市打造生物医药产业新高地。项目建成后,将显著提升悦康药业在核酸药物领域的研发和生产能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633370116","title":"5月7日悦康药业涨5.21%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633370116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633370116?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:33","pubTimestamp":1778142828,"startTime":"0","endTime":"0","summary":"证券之星消息,5月7日悦康药业涨5.21%,收盘报21.21元,换手率2.95%,成交量13.28万手,成交额2.75亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为11.12亿元,最新净值1.6834,较上一交易日上涨0.45%,近一年上涨24.36%。该公募基金现任基金经理为赵伟 王超。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700026719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","159938","BK1515","09939","BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633922227","title":"股市必读:悦康药业(688658)股东户数1.48万户,较上期增加13.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633922227","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633922227?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:05","pubTimestamp":1778015116,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,悦康药业报收于19.6元,上涨1.71%,换手率2.48%,成交量11.14万手,成交额2.19亿元。来自公司公告汇总:悦康药业2026年第一季度营业收入为5.56亿元,同比下降3.70%;净利润为-3310.60万元,亏损同比收窄。股本股东变化股东户数变动截至2026年3月31日,悦康药业股东户数为1.48万户,较2月28日增加1745.0户,增幅13.4%;户均持股数量由上期的3.46万股下降至3.05万股,户均持股市值为52.21万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628423","title":"每周股票复盘:悦康药业(688658)Q1净亏收窄至-3310.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632628423?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:32","pubTimestamp":1777671133,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,悦康药业报收于19.6元,较上周的19.28元上涨1.66%。本周,悦康药业4月30日盘中最高价报20.14元。本周关注点来自业绩披露要点:悦康药业2026年一季报显示归母净利润为-3310.6万元,同比上升32.81%。股本股东变化截至2026年3月31日,悦康药业股东户数为1.48万户,较2月28日增加1745.0户,增幅13.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631380576","title":"悦康药业(688658)披露2026年第一季度报告,4月30日股价上涨1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631380576","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631380576?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:36","pubTimestamp":1777545379,"startTime":"0","endTime":"0","summary":"公司于2026年4月30日披露《2026年第一季度报告》。公告显示,悦康药业2026年第一季度营业收入为556,037,071.94元,同比下降3.70%;归属于上市公司股东的净利润为-33,106,026.51元,亏损同比收窄;经营活动产生的现金流量净额为44,470,251.00元,同比下降45.13%;研发投入合计92,647,729.79元,占营业收入比例为16.66%;总资产为5,187,150,678.66元,归属于上市公司股东的所有者权益为3,282,101,354.88元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260430/32194684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516858","title":"图解悦康药业一季报:第一季度单季净利润同比增长32.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631516858?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:51","pubTimestamp":1777463511,"startTime":"0","endTime":"0","summary":"证券之星消息,悦康药业2026年一季报显示,一季度公司主营收入5.56亿元,同比下降3.7%;归母净利润-3310.6万元,同比上升32.81%;扣非净利润-3734.44万元,同比上升30.16%;负债率36.92%,投资收益77.99万元,财务费用385.75万元,毛利率56.93%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630807747","title":"每周股票复盘:悦康药业(688658)募投项目变更用于新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2630807747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630807747?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:31","pubTimestamp":1777156260,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,悦康药业报收于19.28元,较上周的19.93元下跌3.26%。本周,悦康药业4月23日盘中最高价报20.46元。悦康药业当前最新总市值86.76亿元,在化学制药板块市值排名64/150,在两市A股市值排名2273/5200。公司公告汇总悦康药业集团股份有限公司因部分募投项目变更及结项,将节余募集资金用于新增募投项目“小核酸药物及mRNA疫苗研发项目”及永久补充流动资金。专户仅用于特定募投项目募集资金的存放与使用,不得存放非募集资金或作其他用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015184","title":"4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629015184?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:30","pubTimestamp":1776846615,"startTime":"0","endTime":"0","summary":"证券之星消息,4月22日悦康药业涨5.49%,收盘报19.8元,换手率3.02%,成交量13.59万手,成交额2.64亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为9.48亿元,最新净值1.717,较上一交易日下跌1.05%,近一年上涨33.73%。该公募基金现任基金经理为赵伟 王超。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09939","BK0239","159938","BK1515","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627404205","title":"4月15日悦康药业涨8.59%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404205","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404205?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:10","pubTimestamp":1776240613,"startTime":"0","endTime":"0","summary":"证券之星消息,4月15日悦康药业涨8.59%,收盘报20.61元,换手率5.08%,成交量22.85万手,成交额4.56亿元。重仓悦康药业的前十大公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共24家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元,最新净值3.225,较上一交易日下跌0.52%,近一年上涨17.57%。该公募基金现任基金经理为赵伟。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439462","title":"悦康药业最新公告:子公司YKYY026注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627439462?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:49","pubTimestamp":1776073771,"startTime":"0","endTime":"0","summary":"悦康药业公告称,公司子公司北京悦康科创、杭州天龙近日获得国家药监局核准签发的关于YKYY026注射液的《药物临床试验批准通知书》。该药品为编码水痘-带状疱疹病毒gE蛋白抗原的mRNA疫苗,用于预防带状疱疹,同意在≥40岁人群中开展I期临床试验。YKYY026注射液采用自主知识产权的突变位点组合及LNP递送系统,此前已获得美国FDA临床试验批准。公司将积极推进研发及注册进度,并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300024084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659781","title":"悦康药业(688658)披露子公司YKYY018雾化吸入剂获人偏肺病毒感染临床试验批准,4月3日股价下跌3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659781","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659781?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:52","pubTimestamp":1775209935,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,悦康药业报收于19.29元,较前一交易日下跌3.07%,最新总市值为86.8亿元。悦康药业集团股份有限公司全资子公司北京悦康科创医药科技股份有限公司近日获得国家药品监督管理局关于YKYY018雾化吸入剂用于治疗与预防人偏肺病毒感染的两份《药物临床试验批准通知书》。此前该产品已获NMPA和FDA批准开展针对呼吸道合胞病毒感染的临床试验。目前全球尚无获批的人偏肺病毒感染治疗药物或疫苗,临床需求迫切。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624577141","title":"悦康药业最新公告:创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2624577141","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624577141?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:50","pubTimestamp":1775123412,"startTime":"0","endTime":"0","summary":"悦康药业公告称,公司全资子公司悦康科创近日获得国家药品监督管理局关于同意YKYY018雾化吸入剂用于人偏肺病毒治疗与预防的两份《药物临床试验批准通知书》。截至目前,全球范围内尚未有获批上市的人偏肺病毒感染治疗药物和疫苗,临床治疗和预防领域存在显著且迫切的未被满足需求。该产品近日也已获得FDA核准签发的关于YKYY018雾化吸入剂用于预防和治疗人偏肺病毒感染进行临床试验的函告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200032595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","688658","BK0239","159646","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622458893","title":"股市必读:悦康药业(688658)今年截至3月26日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622458893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622458893?lang=zh_cn&edition=full","pubTime":"2026-03-27 02:49","pubTimestamp":1774550947,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,悦康药业报收于17.1元,下跌0.29%,换手率1.42%,成交量6.37万手,成交额1.1亿元。当日关注点来自交易信息汇总:悦康药业3月26日收盘报17.1元,跌0.29%,当日成交637.31万元,年内累计跌幅达22.04%。前10个交易日资金流向情况:主力资金累计净流出653.27万元,股价累计下跌5.73%;融资余额累计减少104.78万元,融券余量累计增加7026股。该股最近90天内共有1家机构给出评级,买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700004515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043217","title":"三部门发文规范中医药服务管理;药监局助力器械临床创新成果转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043217","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622043217?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:06","pubTimestamp":1774404374,"startTime":"0","endTime":"0","summary":"政策动向三部门发文规范基层医疗卫生机构中医药服务管理3月24日,国家中医药局、国家卫生健康委、国家疾控局联合发布《乡镇卫生院社区卫生服务中心中医药服务管理基本规范》,明确乡镇卫生院、社区卫生服务中心应能提供中药饮片、针刺、艾灸、刮痧砭术、拔罐、中医微创、推拿、敷熨熏浴、骨伤、肛肠等项目中的6类10项以上中医药技术方法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253683741047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253683741047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300006","688658","BK0070","BK0239","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621054379","title":"悦康药业(688658.SH):YKYY018雾化吸入剂治疗与预防人偏肺病毒感染的适应症获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621054379","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621054379?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:46","pubTimestamp":1774338399,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业(688658.SH)公告,公司全资子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY018雾化吸入剂用于人偏肺病毒治疗与预防的临床试验申请的函告。公告显示,YKYY018雾化吸入剂是公司依托全流程AI平台自主开发的一款国际原创的膜融合抑制剂药物。YKYY018项目针对呼吸道合胞病毒(RSV)感染的临床Ⅰ期研究正在稳步推进中,本次获批人偏肺病毒治疗与预防适应症,标志着该管线布局从单一病毒向重要呼吸道病毒谱全面拓展,为婴幼儿、老年人等高风险人群提供更全面的防治选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4588","LABU","BK4585","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621467307","title":"股市必读:悦康药业年报 - 第四季度单季净利润同比下降33.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621467307","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621467307?lang=zh_cn&edition=full","pubTime":"2026-03-23 03:32","pubTimestamp":1774207937,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,悦康药业报收于17.9元,下跌2.45%,换手率1.25%,成交量5.64万手,成交额1.03亿元。来自:悦康药业2025年归母净利润亏损2.62亿元,同比下降312.09%。股本股东变化股东户数变动近日悦康药业披露,截至2026年2月28日公司股东户数为1.3万户,较12月31日增加3327.0户,增幅为34.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300001409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621606799","title":"每周股票复盘:悦康药业(688658)2025年净亏损2.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621606799","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621606799?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:57","pubTimestamp":1774119428,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,悦康药业报收于17.9元,较上周的17.98元下跌0.44%。本周,悦康药业3月17日盘中最高价报19.7元。悦康药业当前最新总市值80.55亿元,在化学制药板块市值排名64/150,在两市A股市值排名2332/5190。本周关注点来自业绩披露要点:悦康药业2025年归母净利润为-2.62亿元,同比下降312.09%。股本股东变化截至2026年2月28日,悦康药业股东户数为1.3万户,较2025年12月31日增加3327户,增幅达34.33%。2025年度营业收入扣除与主业无关收入629.98万元,占比0.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620573918","title":"悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620573918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620573918?lang=zh_cn&edition=full","pubTime":"2026-03-20 21:07","pubTimestamp":1774012026,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业 发布2025年年度报告,报告期内,公司实现营业收入24.46亿元,同比下降35.30%。归属于上市公司股东的净亏损2.62亿元。基本每股亏损0.59元。报告期内,公司继续保持高比例研发投入,研发费用同比上升,高比例的研发投入对公司净利润产生了一定影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778594026615,"stockEarnings":[{"period":"1week","weight":0.1163},{"period":"1month","weight":0.1682},{"period":"3month","weight":-0.0382},{"period":"6month","weight":0.0191},{"period":"1year","weight":0.4366},{"period":"ytd","weight":-0.0323}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0599},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.2642},{"period":"ytd","weight":0.0645}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"悦康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14764人(较上一季度增加13.40%)","perCapita":"30479股","listingDate":"2020-12-24","address":"北京市大兴区北京经济技术开发区宏达中路6号","registeredCapital":"45000万元","survey":" 悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是银杏叶提取物注射液、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠(自产)、注射用头孢呋辛钠(明可欣)、活心丸(浓缩丸)。公司连续多年入选工信部医药工业百强,连续多年入选工信部中国医药研发产品线最佳工业企业。在2025年第42届全国医药工业信息年会上公司又一次强势入围,并荣获“2025年中国医药研发产品线工业企业优秀案例”荣誉;此外,公司荣获“2025中国药品研发综合实力百强”、“2025中国中药研发实力”第6位等荣誉。公司已获国家科技进步二等奖2项,承担省部级以上科技项目50余项,国家级重大专项23项,已获授权专利400余项,公司创新能力持续增强。","listedPrice":24.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"悦康药业,688658,悦康药业股票,悦康药业股票老虎,悦康药业股票老虎国际,悦康药业行情,悦康药业股票行情,悦康药业股价,悦康药业股市,悦康药业股票价格,悦康药业股票交易,悦康药业股票购买,悦康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}